Loading...
XNAS
SNPX
Market cap11mUSD
, Last price  
USD
Name

Synaptogenix Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
9,755,549.64
Div Yield, %
Shrs. gr., 5y
-26.99%
Rev. gr., 5y
%
Revenues
0k
Net income
13.56t
P
-11,022,286-14,756,043-14,249,984-12,604,087-5,458,067-6,038,50413,558,458,000,000
CFO
-4.88t
L+94,409,153.52%
-7,696,771-11,886,809-8,102,398-8,710,725-11,211,245-5,173,209-4,883,988,000,000

Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
IPO date
Dec 07, 2020
Employees
5
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
6,810,732,000
8,320
16,141
Unusual Expense (Income)
NOPBT
(6,810,732,000)
(8,320)
(16,141)
NOPBT Margin
Operating Taxes
(789,909,000)
(116)
Tax Rate
NOPAT
(6,020,823,000)
(8,320)
(16,025)
Net income
13,558,458,000
-224,533,494.36%
(6,039)
10.63%
(5,458)
-56.70%
Dividends
(950,918,000)
(641)
(116)
Dividend yield
22,212,836.95%
20.23%
0.06%
Proceeds from repurchase of equity
(8,633)
(882)
359
BB yield
201.67%
27.84%
-0.18%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
9,943,000,000
1,253
1,880
Net debt
(17,656,221,000)
(30,662)
(37,478)
Cash flow
Cash from operating activities
(4,883,988,000)
(5,173)
(11,211)
CAPEX
(3)
(7)
Cash from investing activities
(1,000,000,000)
(2,003)
(7)
Cash from financing activities
(5,121,289,000)
(1,641)
14,483
FCF
(6,020,822,994)
(8,317)
(16,027)
Balance
Cash
17,656,221,000
30,100
37,478
Long term investments
562
Excess cash
17,656,221,000
30,662
37,478
Stockholders' equity
(47,169,205,994)
(32,370)
(17,109)
Invested Capital
63,888,717,994
59,208
54,404
ROIC
ROCE
EV
Common stock shares outstanding
1,234
466
6,989
Price
3.47
-48.95%
6.80
-76.56%
29.00
-86.37%
Market cap
4,281
35.12%
3,168
-98.44%
202,687
-81.00%
EV
(17,656,216,719)
(26,257)
167,930
EBITDA
(6,805,152,000)
(8,314)
(16,135)
EV/EBITDA
2.59
3.16
Interest
20,671
Interest/NOPBT